{"schema_version":"1.0","type":"article","title":"RevMed Upends Pancreatic Cancer Again: The RAS Combination Era Has Arrived","url":"https://drugnews.com.tw/articles/2026-07-17-revmed-ras-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-07-17-revmed-ras-en.md","lang":"en","date":"2026-07-17","publish_at":"2026-07-17T09:46:13+08:00","updated_at":"2026-07-17","category":"商業分析系列","topic":"商業分析系列","tags":["Business Analysis","Revolution Medicines","RevMed","pancreatic cancer","KRAS G12D","RAS(ON)","zoldonrasib","daraxonrasib","ESMO GI 2026","clinical data","combination therapy","oncology"],"summary":"Daraxonrasib has already raised the bar with phase 3 overall-survival data. Early zoldonrasib combinations now suggest that pancreatic cancer's RAS competition is shifting from single agents to treatment ecosystems.","key_points":[],"facts":[],"sections":["01 | Why Pancreatic Cancer Is So Difficult: KRAS Is the Central Switch","02 | Zoldonrasib Plus Daraxonrasib: Depth and Breadth, Not Just 1 + 1","03 | The Signals Are Strong, but the Samples Are Still Early","04 | RevMed Is Turning RAS Into a Franchise","05 | The International RAS Field Will Be Repriced","Conclusion | The “King of Cancers” Has Not Been Defeated, but the Treatment Logic Has Changed","References","Disclaimer"],"references":[{"title":"[Revolution Medicines","source":"Phase 1/2 clinical data for zoldonrasib combination regimens, July 2, 2026]","date":"","url":"https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-presents-phase-12-clinical-data-zoldonrasib"},{"title":"[ClinicalTrials.gov","source":"RASolute 302: daraxonrasib versus investigator's choice in previously treated metastatic PDAC (NCT06625320)]","date":"","url":"https://clinicaltrials.gov/study/NCT06625320"},{"title":"[Revolution Medicines","source":"RASolute 302 ASCO plenary presentation and overall-survival results]","date":"","url":"https://ir.revmed.com/node/13046/pdf"},{"title":"[ClinicalTrials.gov","source":"Zoldonrasib phase 1/1b study (NCT06040541)]","date":"","url":"https://clinicaltrials.gov/study/NCT06040541"},{"title":"[ClinicalTrials.gov","source":"RASolute 305 first-line phase 3 study (NCT07621718)]","date":"","url":"https://clinicaltrials.gov/study/NCT07621718"},{"title":"[Revolution Medicines","source":"First-quarter 2026 corporate and pipeline update]","date":"","url":"https://ir.revmed.com/node/12976/pdf"},{"title":"[ClinicalTrials.gov","source":"MRTX1133 study in advanced solid tumors with KRAS G12D mutation (NCT05737706)]","date":"","url":"https://clinicaltrials.gov/study/NCT05737706"},{"title":"[ClinicalTrials.gov","source":"LY4066434 study in KRAS-mutant solid tumors (NCT06607185)]","date":"","url":"https://clinicaltrials.gov/study/NCT06607185"}],"images":[{"alt":"Why pancreatic cancer is difficult: KRAS G12D functions as a central driver of RAS signaling","url":"https://drugnews.com.tw/assets/articles/revmed-ras-en/figure-01.webp"},{"alt":"Zoldonrasib provides mutation-specific depth while daraxonrasib broadens blockade across RAS escape routes","url":"https://drugnews.com.tw/assets/articles/revmed-ras-en/figure-02.webp"},{"alt":"Early zoldonrasib combination cohorts reported notable response and disease-control signals, with longer follow-up still required","url":"https://drugnews.com.tw/assets/articles/revmed-ras-en/figure-03.webp"},{"alt":"RevMed is organizing daraxonrasib and mutation-selective agents into a multi-line RAS combination franchise","url":"https://drugnews.com.tw/assets/articles/revmed-ras-en/figure-04.webp"}],"cover_image":"https://drugnews.com.tw/assets/articles/revmed-ras-en/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-07-17）。RevMed Upends Pancreatic Cancer Again: The RAS Combination Era Has Arrived。https://drugnews.com.tw/articles/2026-07-17-revmed-ras-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{"zh-Hant":"2026-07-17-revmed-ras.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}